Cardiac Allograft
Cardiac Allograft - Related Videos
08:30
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
0 Views •
Cited by 11 •
2022
We present a protocol for utilizing a normothermic ex vivo sanguinous perfusion system for the delivery of therapeutics to an entire cardiac allograft in a porcine heterotopic heart transplant model.
09:14
Surgical Approach to Full Soft Tissue Face Allograft Procurement for Vascularized Composite Allotransplantation
0 Views •
2025
This protocol details the surgical technique used to harvest and prepare a full-face allograft for transplantation in patients with severe facial disfigurements, focusing primarily on soft tissue procurement with limited bony harvest restricted to the nasal framework.
05:10
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
0 Views •
Cited by 5 •
2010
This protocol describes the isolation and dissociation of mouse medulloblastoma tissue, and subsequent allografting of the tumor cells into immunocompromised recipient mice in order to initiate secondary medulloblastoma.
13:16
Computed Tomography and Optical Imaging of Osteogenesis-angiogenesis Coupling to Assess Integration of Cranial Bone Autografts and Allografts
0 Views •
Cited by 7 •
2015
Implantation of autologous and allogeneic bone grafts constitute accepted approaches to treat major craniofacial bone loss. Yet the effect of graft composition on the interplay among neovascularization, cell differentiation and bone formation is unclear. We present a multimodal imaging protocol aimed to elucidate the angiogenesis-osteogenesis interdependence at the graft proximity.
08:25
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
0 Views •
Cited by 11 •
2015
Streptococcus pneumoniae forms discrete non-purulent microscopic lesions in the heart. Outlined is the protocol for a murine model of cardiac microlesion formation. Instruction is provided on microlesion visualization using microscopy, discrimination between early and late microlesions, and methods to detect cardiac remodeling in hearts of convalescent animals.
FAQs
The recipient’s immune system detects donor antigens, including human leukocyte antigens, as foreign. This recognition can activate T cells, which may then damage graft tissue. Because this response is directed at differences between donor and recipient, tissue matching and ongoing rejection surveillance are central to protecting the transplanted heart and preserving its function.
Immunosuppressive therapy reduces the immune response that can injure a cardiac allograft, but treatment requires careful monitoring. Clinical management must balance control of immune-mediated damage with the recipient’s broader health needs, including infection prevention. Monitoring therefore supports continued graft protection while helping clinicians assess long-term graft function.
Surveillance addresses both acute and chronic rejection because graft injury can be an important concern at different stages after transplantation. Monitoring is part of a broader assessment of graft function rather than a single early check. Detecting concerning changes supports timely clinical management aimed at maintaining circulatory support and long-term transplant benefit.
Tissue matching compares relevant donor and recipient characteristics before transplantation, including factors associated with immune recognition. Its purpose is to inform selection and reduce the likelihood that the recipient’s immune system will strongly identify the graft as foreign. Matching does not replace immunosuppressive therapy or follow-up, so recipients still require rejection surveillance and graft-function assessment.
Post-transplant surveillance focuses on acute and chronic rejection, infection prevention, and long-term graft function. These areas address both immune-mediated injury and complications that may affect the recipient or transplanted heart. Regular assessment helps clinicians determine whether the graft continues to provide effective circulatory support and whether management needs adjustment.
A cardiac allograft may be considered for selected patients with advanced heart failure that is otherwise untreatable. The potential benefits include effective circulatory support, improved survival, and better quality of life. Suitability depends on clinical evaluation, tissue matching, and the ability to undergo continuing management for rejection, infection prevention, and graft function.